Similar articles

• Statins for Primary Prevention of Cardiovascular Disease-With PREVENT, What's a Clinician to Do?

  Khan SS, Lloyd-Jones DM. Khan SS, et al. JAMA. 2024 Sep 24;332(12):961-962. doi: 10.1001/jama.2024.13887. JAMA. 2024. PMID: 39073988
• Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.

  Pavlović J, Greenland P, Deckers JW, Kavousi M, Hofman A, Ikram MA, Franco OH, Leening MJ. Pavlović J, et al. Eur J Prev Cardiol. 2018 Mar;25(4):420-431. doi: 10.1177/2047487317743352. Epub 2017 Nov 24. Eur J Prev Cardiol. 2018. PMID: 29171772 Free PMC article.
• The New 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease.

  Bittner V. Bittner V. Circulation. 2020 Dec 22;142(25):2402-2404. doi: 10.1161/CIRCULATIONAHA.119.040625. Epub 2019 Mar 17. Circulation. 2020. PMID: 30879338 No abstract available.
• Progress in prevention: should we screen for risk factors or disease? A current debate in the prevention of cardiovascular events.

  Dennison CR, Hughes S. Dennison CR, et al. J Cardiovasc Nurs. 2009 Jan-Feb;24(1):18-20. doi: 10.1097/01.JCN.0000343558.14237.70. J Cardiovasc Nurs. 2009. PMID: 19114796 Review. No abstract available.
• Cardiovascular risk assessment and lipid modification: NICE guideline.

  Duerden M, O'Flynn N, Qureshi N. Duerden M, et al. Br J Gen Pract. 2015 Jul;65(636):378-80. doi: 10.3399/bjgp15X685933. Br J Gen Pract. 2015. PMID: 26120133 Free PMC article. Review. No abstract available.